Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astymin
- Development stage
- Phase 4
- Lead developer
- TIL Healthcare
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Astymin is a parenteral amino acid infusion solution developed by Tablets India Limited in technical collaboration with Ajinomoto Pharma Co. Ltd. Japan. It is a small molecule nutritional formulation composed of pure crystalline essential amino acids, including L-arginine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, and L-valine, along with glycine and sorbitol. Administered intravenously, it provides essential building blocks for protein synthesis and metabolic processes in patients who cannot tolerate oral nutrition. It is used to correct negative nitrogen balance, support immunity, and aid recovery in clinical conditions such as pre- and post-operative care and other states requiring amino acid supplementation.
- Brand names
- AstyminAstymin-3Astymin3Astymin 3Astymin-SN
Beyond the preview
Go deeper on Astymin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astymin.